Currently, several clinical trials are evaluating the use of Chk1 inhibitors for the treatment of patients with either solid tumors or hematological malignances (ClinicalTrials.gov Identifier: NCT02203513 and NCT03495323). This evidence concerns the gene CHEK1 and hematologic disorder.